Aptamer-based targeted therapy

被引:389
作者
Zhu, Guizhi [1 ]
Chen, Xiaoyuan [2 ]
机构
[1] Virginia Commonwealth Univ, Dept Pharmaceut, Sch Pharm, Richmond, VA 23298 USA
[2] Natl Inst Biomed Imaging & Bioengn, Lab Mol Imaging & Nanomed, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
Aptamer; Nucleic acid therapeutics; Aptamer-drug conjugate; Drug delivery; Targeted immunotherapy; IN-VITRO SELECTION; PROSTATE-CANCER CELLS; CD8(+) T-CELLS; DNA APTAMER; OLIGONUCLEOTIDE APTAMER; MOLECULAR RECOGNITION; PHOTODYNAMIC THERAPY; SYSTEMATIC EVOLUTION; VIVO DELIVERY; HIGH-AFFINITY;
D O I
10.1016/j.addr.2018.08.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Precision medicine holds great promise to harness genetic and epigenetic cues for targeted treatment of a variety of diseases, ranging from many types of cancers, neurodegenerative diseases, to cardiovascular diseases. The proteomic profiles resulting from the unique genetic and epigenetic signatures represent a class of relatively well accessible molecular targets for both interrogation (e.g., diagnosis, prognosis) and intervention (e.g., targeted therapy) of these diseases. Aptamers are promising for such applications by specific binding with cognate disease biomarkers. Nucleic acid aptamers are a class of DNA or RNA with unique three-dimensional conformations that allow them to specifically bind with target molecules. Aptamers can be relatively easily screened, reproducibly manufactured, programmably designed, and chemically modified for various biomedical applications, including targeted therapy. Aptamers can be chemically modified to resist enzymatic degradation or optimize their pharmacological behaviors, which ensured their chemical integrity and bioavailability under physiological conditions. In this review, we will focus on recent progress and discuss the challenges and opportunities in the research areas of aptamer-based targeted therapy in the forms of aptamer therapeutics and aptamer-drug conjugates (ApDCs). Published by Elsevier B.V.
引用
收藏
页码:65 / 78
页数:14
相关论文
共 216 条
[1]   Radioimmunotherapy with Yttrium-90 Ibritumomab tiuxetan for patients with relapsed cd20+ B-Cell non-Hodgkin’s Lymphoma [J].
Alcindor T. ;
Witzig T.E. .
Current Treatment Options in Oncology, 2002, 3 (4) :275-282
[2]   Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells [J].
Alshaer, Walhan ;
Hillaireau, Herve ;
Vergnaud, Juliette ;
Ismail, Said ;
Fattal, Elias .
BIOCONJUGATE CHEMISTRY, 2015, 26 (07) :1307-1313
[3]   The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine [J].
Alshamsan, Aws ;
Hamdy, Samar ;
Samuel, John ;
El-Kadi, Ayman O. S. ;
Lavasanifar, Afsaneh ;
Uludag, Hasan .
BIOMATERIALS, 2010, 31 (06) :1420-1428
[4]   Rational design of a small molecule-responsive intramer controlling transgene expression in mammalian cells [J].
Auslaender, David ;
Wieland, Markus ;
Auslaender, Simon ;
Tigges, Marcel ;
Fussenegger, Martin .
NUCLEIC ACIDS RESEARCH, 2011, 39 (22) :e155
[5]   Bispecific T-Cell Engaging Antibodies for Cancer Therapy [J].
Baeuerle, Patrick A. ;
Reinhardt, Carsten .
CANCER RESEARCH, 2009, 69 (12) :4941-4944
[6]   Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular α-Particle Therapy of Cancer [J].
Bandekar, Amey ;
Zhu, Charles ;
Jindal, Rohit ;
Bruchertseifer, Frank ;
Morgenstern, Alfred ;
Sofou, Stavroula .
JOURNAL OF NUCLEAR MEDICINE, 2014, 55 (01) :107-114
[7]   Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer [J].
Bates, Paula J. ;
Laber, Damian A. ;
Miller, Donald M. ;
Thomas, Shelia D. ;
Trent, John O. .
EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2009, 86 (03) :151-164
[8]   Antiproliferative activity of G-rich oligonucleotides correlates with protein binding [J].
Bates, PJ ;
Kahlon, JB ;
Thomas, SD ;
Trent, JO ;
Miller, DM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (37) :26369-26377
[9]   In Vitro Selection of DNA Aptamers to Glioblastoma Multiforme [J].
Bayrac, Abdullah Tahir ;
Sefah, Kwame ;
Parekh, Parag ;
Bayrac, Ceren ;
Gulbakan, Basri ;
Oktem, Huseyin Avni ;
Tan, Weihong .
ACS CHEMICAL NEUROSCIENCE, 2011, 2 (03) :175-181
[10]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352